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Abstract
Allosteric modulation of membrane receptors is a widespread mechanism by which endogenous
and exogenous agents regulate receptor function. For example, several members of the nicotinic
receptor family are modulated by physiological concentrations of extracellular calcium ions. In this
paper, we examined conformational changes underlying this modulation and compare these with
changes evoked by ACh. Two sets of residues in the 7 acetylcholine receptor extracellular
domain were mutated to cysteine and analyzed by measuring the rates of modification by the thiol-
specific reagent 2-aminoethylmethane thiosulfonate. Using Ba2+ as a surrogate for Ca2+, we found
a divalent-dependent decrease the modification rates of cysteine substitutions at M37 and M40,
residues at which rates were also slowed by ACh. In contrast, Ba2+ had no significant effect at N52C,
a residue where ACh increased the rate of modification. Thus divalent modulators cause some but
not all of the conformational effects elicited by agonist. Cysteine substitution of either of two
glutamates (E44 or E172), thought to participate in the divalent cation binding site, caused a loss of
allosteric modulation, yet Ba2+ still had a significant effect on modification rates of these residues.
In addition, the effect of Ba2+ at these residues did not appear to be due to direct occlusion. Our
data demonstrate that modulation by divalent cations involves substantial conformational changes
in the receptor extracellular domain. Our evidence also suggests the modulation occurs via a
binding site distinct from one which includes either (or both) of the conserved glutamates at E44 or
E172.
Background
Allosteric modulation of membrane receptors is increas-
ingly recognized as a common mechanism used to control
cellular signal transduction [1,2]. In general, allosteric
modulator binding causes changes in the response of the
receptor to the "native ligand", presumably by altering the
energetic barrier between resting and activated conforma-
tions. In most cases the modulator does not activate the
target receptor in the absence of agonist. While there has
been substantial progress in identifying the binding sites
for many allosteric modulators (for example, [3]), the
mechanisms by which modulators induce their effects
remain poorly defined.
Published: 13 January 2009
BMC Pharmacology 2009, 9:1 doi:10.1186/1471-2210-9-1
Received: 19 September 2008
Accepted: 13 January 2009
This article is available from: http://www.biomedcentral.com/1471-2210/9/1
© 2009 McLaughlin et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Pharmacology 2009, 9:1 http://www.biomedcentral.com/1471-2210/9/1
Page 2 of 13
(page number not for citation purposes)
Some of the best examples of allosteric modulation
involve members of the Cys-loop family of ligand-gated
ion channels that includes nicotinic AChRs as well as the
GABAA, glycine, and 5-hydroxytryptamine-3 receptors [4].
Cys-loop receptors transduce the energy of agonist bind-
ing into conformational changes that lead to channel
opening [5]. All family members share a similar structure:
they are transmembrane proteins assembled from five
homologous or identical subunits. Each of these subunits
is comprised of a large amino terminal extracellular
domain (ECD), a large intracellular loop, and a four -
helix bundle forming a transmembrane domain (TMD).
Recent studies aimed at identifying the structural basis for
ligand gating have focused on the "transition zone" [6] a
region of the receptor at the boundary between the ECD
the TMD. The transition zone includes structural elements
thought to link the TMD and the ligand binding site [7-9].
While the evidence for this linkage is preliminary, a
number of experimental approaches have unequivocally
mapped the site for ligand binding to the interface of adja-
cent subunit ECDs [5]. More recently, the crystal struc-
tures of ACh-binding proteins (AChBPs) from Lymnea,
Aplysia, and Bulinus  [10-12] have provided a structural
context for these biochemical and functional studies. The
AChBPs are soluble proteins that act as ACh buffers in
invertebrates [13]; they share both sequence and func-
tional homology to the ECD of Cys-loop receptors. Earlier
this year another structure, that of a homologous bacterial
ligand-gated ion channel, was added to the structural
database of Cys-loop receptors [14]. These crystal struc-
tures have been used to develop and refine homology
models of Cys-loop receptors [15,16]. Our goal is to use
these refined models to test specific mechanistic hypothe-
ses that attempt to explain the dynamics of both ligand-
induced receptor activation and allosteric modulation [7-
9,17].
Many neuronal nicotinic AChRs exhibit positive allosteric
modulation by physiological concentrations of Ca2+
[18,19]. In 7 nAChRs (but not other neuronal AChRs)
Ba2+ or Sr2+ can elicit effects similar to Ca2+ [18,20,21].
This modulation consists of an increase in both the effi-
cacy and the potency of ACh. The functional effects of
divalents are similar to those caused by an emerging class
of nicotinic modulating drugs collectively referred to as
PAMs (positive allosteric modulators; [22]). Thus one
rationale for a mechanistic characterization of divalent
modulation of 7 AChRs is to serve as a model for studies
of drugs such as PAMs developed to elicit a similar effect.
Previous studies demonstrated that the modulation of 7
AChRs by divalent cations is independent of divalent cat-
ion permeation, suggesting that the binding site for mod-
ulation is extracellular [21]. In addition several studies
have demonstrated the importance of conserved ECD
glutamate residues (E44 and E172 in chick 7) in divalent
cation modulation, and it has been suggested that these
may form the allosteric modulation binding site
[15,20,23]. In this paper, we tested the hypothesis that
conformational changes evoked by divalent cation modu-
lators of the 7 AChR are similar to those evoked by ACh.
In addition, we examined whether E44  and E172  are
required for divalent cation-evoked conformational
changes. We found some similarities between Ba2+ evoked
conformational changes and those caused by ACh. Sur-
prisingly, we also found that the effects Ba2+ on modifica-
tion rates did not require E44 or E172, suggesting that these
residues do not form the divalent cation binding site.
Results
The substituted cysteine accessibility method (SCAM) is
an established experimental approach to examine protein
conformational dynamics [24]. We previously used this
approach to scan regions of the chick 7 AChR and iden-
tified residues where the rates of thiol-specific modifica-
tion by MTSEA were altered by ACh [23,25]. We consider
two alternative mechanisms for ACh-dependent effects on
modification rates. If the substituted cysteine is at a posi-
tion that is part of the agonist binding site [5], then the
effect of ACh could be due to steric occlusion. Alterna-
tively, if the substituted cysteine is not near the binding
site, then we infer that a change in modification rates is a
result of conformational or electrostatic change induced
by agonist-dependent activation. In this way, these resi-
dues serve as reporters of intramolecular changes during
receptor activation.
SCAM can be used in the same way to identify conforma-
tional changes caused by allosteric modulators. Figure 1
shows a representation of the region of the 7 ECD tar-
geted in this study. A discrete region of the inner  sheet,
including M37, M40, and N52 was initially chosen to exam-
ine the effects of the divalent cation Ba2+ on MTSEA mod-
ification rates. We also examined the effects of Ba2+ at
transition zone residues previously implicated in modula-
tion by divalent cations, including E44, E172, as well as an
adjacent position N170. All of the cysteine replacements at
these residues have previously been shown to exhibit ago-
nist-sensitive MTSEA modification rates, allowing us a
basis for comparison for the effects of Ba2+.
For these studies we began by confirming the modulatory
effects of Ba2+ on ACh-dependent activation of our paren-
tal phenotype, 7 C115A/L247T. Wild-type 7 AChRs
exhibit a complex positive modulation by divalent cations
such as Ca2+ or Ba2+ that includes increases in both efficacy
and potency [20]. In contrast, receptors with the L247T
phenotype typically exhibit a simplified modulatory
response consisting only of a 5- to 10-fold left shift in the
ACh dose-response.BMC Pharmacology 2009, 9:1 http://www.biomedcentral.com/1471-2210/9/1
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A model of the 7 AChR extracellular domain Figure 1
A model of the 7 AChR extracellular domain. Ribbon cartoon showing two of the five subunits viewed from the out-
side. In the subunit to the left of the central interface (yellow), the outer  sheet in is highlighted in orange, the transition zone 
E44 residue is orange, and the W148 residue is shown in gray to identify the ACh binding pocket (Zhong et. al., 1998). The sub-
unit to the right shows a view of the inner sheet (teal), and other residues targeted in this study. The sequence surround 
mutants characterized in this study is shown beneath the cartoon: M37, M40 cyan; N52 green; N170 blue; E172 purple.BMC Pharmacology 2009, 9:1 http://www.biomedcentral.com/1471-2210/9/1
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Figure 2A shows the effect of 10 mM Ba2+ on the 7 C115A/
L247T receptor. There was a leftward shift in the dose-
response curve corresponding to a ~10 fold decrease in
EC50 (increase in potency). Of note, we do not see an
effect of Ba2+ on efficacy in the parental background. We
suspect this is due to the higher gating constant of recep-
tors with the L247T mutation. Figure 2B shows that modu-
lation by Ba2+  was eliminated in the E44C mutant,
confirming that this conserved glutamate is required for
Ba2+ binding or allosteric coupling of Ba2+ binding to
ACh-dependent activation. This result is similar to the
effect of an E44Q mutant described in wild-type and L247T
7 AChRs [20,21]. Table 1 provides a compilation of
EC50's, modulatory effects of 10 mM Ba2+, and the maxi-
mal responses of the mutants described in this report.
Neither of the transition zone glutamate mutants (E44C
and E172C) exhibited a positive modulation, while the
N52C mutant displayed a high partial agonism by Ba2+ in
the absence of ACh.
Previously, we measured the effects of ACh on reactivity of
cysteine mutants in the inner  sheet of the chick 7 AChR
[26]. Several residues (M37C, M40C, and N52C) exhibited
a change MTSEA reaction rates in the presence of ACh. We
interpret differences in modification rates in the absence
or presence of ACh to reflect differences in the apparent
accessibility of the introduced cysteine between the unlig-
anded and liganded states. To test if these sites could also
be used as reporters of allosteric modulator-induced con-
formational change we examined the effects of Ba2+ on
rates of MTSEA modification.
Figure 3 shows an example of the protocol used to meas-
ure the thiol modification rate of the receptors with the
M37C mutation. ACh-evoked current amplitudes
decreased following brief, repeated exposure to a limiting
concentration of MTSEA (5 M, 15 seconds). To ensure
that the modification reactions were complete, all rate
measurements included a final prolonged application of
~100-fold higher concentrations of MTSEA (Fig. 3A and
3B, right). Currents measured following this application
represent the endpoint of the reaction between MTSEA
and receptors. When the same protocol included Ba2+ pre-
treatment and co-application with MTSEA (see Methods),
the decreases in current amplitudes were slowed but the
same endpoint was obtained (Fig. 3B). Normalized cur-
rent amplitudes were plotted as a function of the cumula-
tive time of exposure to MTSEA, and pseudo first-order
rates were extracted from the single-exponential fits (Fig.
3C). We observe a significant decrease in the MTSEA mod-
ification rate for M37C (Fig. 4) in the presence of 10 mM
Ba2+, demonstrating that this modulator caused changes
in the conformation or electrostatic environment around
the M37C side chain.
Using the protocol described in Figure 3, we determined
second-order rate constants for modification of the three
reporter residues in the inner  sheet (M37C, M40C, and
N52C). Figure 4A shows mean values of the rate constants
measured in the presence of MTSEA alone, MTSEA plus
ACh, and MTSEA plus Ba2+. We observed significant
decreases in reaction rates of both M37C and M40C in the
presence of 10 mM Ba2+. The effects are quantitatively
similar to those measured in the presence of ACh [26],
consistent with the idea that Ba2+ causes conformational
changes similar to those induced by agonist in this region
of the 7 AChR. To more directly compare the effects of
ACh and Ba2+ on reaction rates, we plot rate constants as
ratios in Figure 4B. This figure highlights the differences in
MTSEA rates under different conditions at these three
positions. In contrast to M37C and M40C, we observed no
significant effect of Ba2+ on MTSEA modification rate of
N52C. This result parallels our previous study in which we
found the effect of ACh on MTSEA modification rate of
N52C was also different from that of neighboring residues
M37C and M40C. Collectively, these results suggest that
divalent cations such as Ba2+ act to promote some, but not
all, of the conformational or electrostatic changes elicited
by ACh. While ACh acts to stabilize the open state, Ba2+
acts to stabilize a state (or states) that are energetic inter-
mediates between closed and open channels.
Modulation by divalent cations is known to require the
conserved acidic residues at E44 and E172 (23, 24). We next
tested whether Ba2+ could cause changes in the rates of
MTSEA modification at E44C, N170C, and E172C. Similar to
residues in the inner  sheet, each of these mutants has
been shown to be a reporter of conformational or electro-
static changes induced by ACh [23,25]. Figure 5A shows
mean values of second order rate constants measured in
the presence of MTSEA alone, MTSEA plus ACh, and
MTSEA plus Ba2+. At N170C, a mutant that showed allos-
teric modulation (Table 1), the rate of MTSEA modifica-
tion in the presence of Ba2+ was the same as that measured
in MTSEA alone, but was different from that measured in
the presence of ACh. This observation suggests that con-
formational or electrostatic changes induced by modula-
tors at this residue are distinct from those induced by
ACh. Differences between the effects of ACh and Ba2+ were
most pronounced at E44C; at this residue, the modifica-
tion rate was ~10 fold higher in the presence of Ba2+ com-
pared to that measured in the presence of ACh (Figure
5B). Surprisingly, despite the fact that both E44C and
E172C show no positive allosteric modulation of ACh cur-
rents by Ba2+ (Fig. 2, Table 2), both exhibited significant
Ba2+-dependent decreases in MTSEA modification rate.
The hypothesized requirement for E44 and E172 in divalent
cation modulation was based upon studies of charge neu-
tralization mutants (E44Q, E172Q) in which modulation isBMC Pharmacology 2009, 9:1 http://www.biomedcentral.com/1471-2210/9/1
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Positive allosteric modulation by divalent cations requires E44 Figure 2
Positive allosteric modulation by divalent cations requires E44. ACh dose-response curves for the parental C115A/
L247T (A) and the E44C mutant (B) in the absence (open squares) and presence (filled squares) of 10 mM BaCl2. Data are fitted 
to the Hill equation (solid lines). The positive allosteric modulation (leftward shift in the dose response curve) typically exhib-
ited by 7 AChRs (A) is lost in the E44C mutant (B). Data are mean values (± SEM) from three determinations, normalized to 
the maximal value of the Hill equation fit of each data set. Hill coefficients for C115A/L247T (A): 2.5 ± 0.2 (open squares, -Ba2+), 
1.9 ± 0.4 (filled squares, +Ba2+); and for the E44C mutant (B) 1.7 ± 0.2 (open squares, -Ba2+), 2.9 ± 0.7 (filled squares, +Ba2+).BMC Pharmacology 2009, 9:1 http://www.biomedcentral.com/1471-2210/9/1
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lost. From these and other studies, both residues were pro-
posed to be participants in a binding site which mediates
the divalent cation allosterism [20,21]. The loss of Ba2+
dependent modulation in E44C or E172C mutations (also
charge neutralization mutations) is consistent with this
proposal, but the effects of Ba2+ on MTSEA modification
rates are not. One possible explanation for these observa-
tions is that Cys replacements at E44 and E172 do not pre-
vent Ba2+ binding, but cause an uncoupling of binding
and allosteric modulation. If Ba2+ binds near E44C and
E172C, the slowed modification rate at E44C or E172C
would be explained by physical occlusion of the thiol
side-chain by bound Ba2+. Alternatively, the glutamates
could be a required component in the transduction path-
way between Ba2+ binding and receptor modulation, but
are not direct participants in the binding site. In this case
divalent cations bind at a different site and elicit confor-
mational or electrostatic changes (detected as changes in
E44C and E172C modification rates), but binding does not
lead to modulation. To test this possibility we examined
MTSEA modification rates at M40C 7 AChRs in which a
second, charge-neutralizing mutation (E172Q) was intro-
duced. We reasoned that if E172 is required for binding of
divalent cations, then the modification rate of M40C
should be insensitive to Ba2+. If, however, Ba2+ binds to
the receptor and causes conformational changes, despite
the mutation at E172, this would be reflected by changes in
the rate of modification of M40C.
We measured dose-response relationships for the M40C/
E172Q double mutant in the absence and presence of 10
mM Ba2+ and confirmed that it was not positively modu-
lated by Ba2+ (Table 1). When the rates of MTSEA modifi-
cation of the M40C in this background were measured, we
found that Ba2+ caused a significant slowing of MTSEA
modification rate (Figure 6). The modification rates of
M40C were independent of the E172 mutation. This result
suggests that the binding site for Ba2+ modulation is some-
where other than a site which includes E44 and E172 in the
7 AChR transition zone [15].
Discussion
The mechanisms of protein allosterism have been the sub-
ject of exhaustive modeling and model refinement since
studies of Monod, Wyman and Changeux [27] and those
of Koshland and colleagues [28]. In the nicotinic recep-
tors, several different types of allosteric behavior have
been described. The concerted, or MWC model, for exam-
ple, refers to the allosteric effect of ligand binding on
channel opening; this model suggested that binding of
multiple agonists acted in concert to yield their "at a dis-
tance" effect. Experimental tests of the MWC model with
combinations of agonists and antagonists suggest that a
stepwise process more accurately describes the activation
process [29,30].
Another type of allosterism seen in some nicotinic recep-
tors is the positive allosteric modulation by divalents such
as Ca2+ or Ba2+ [18,20]. For this type of allosterism, a fun-
damental question is whether the modulation alters the
conformational "pathway" from closed to open states or
simply modifies the kinetics of an agonist-dependent
Table 1: Effects of Ba2+ on ACh evoked currents.
mutant Ach EC50, M (n) ACh Imax AB a 2+ efficacya
control + 10 mM Ba2+
C115A/L247T 1.8 ± 0.4 0.17 ± 0.02 4 6.9 0.1
M37C 2.0 ± 0.5 0.35 ± 0.12 4 0.92 0.2
M40C 7.7 ± 1.1 1.1 ± 0.1 5 3.0 0.1
N52C 2.6 ± 1.3 ndb 5 0.34 0.6
E44C 7.8 ± 0.4 10.1 ± 0.4 4 5.4 0.01
N170Cc 13 ± 1.7 2.1 ± 0.4 6 1.7 0.03
E172Cc 30 ± 2.7 50 ± 9.2 4 1.3 0.02
M40C/E172Qc 85 ± 6.2 134 ± 11 5 0.7 0.02
ACh dose-response measurements in the absence or presence of Ba2+. EC50 estimates are mean values ± SEM.
(a) Ba2+ efficacy is the fraction of maximal ACh-evoked current that is evoked by 10 mM Ba2+ in the absence of ACh. (b) nd: not determined 
because Ba2+ was a strong partial agonist. (c) Mutants studied using co-expression with human RIC-3 (Halevi et al., 2002).BMC Pharmacology 2009, 9:1 http://www.biomedcentral.com/1471-2210/9/1
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Barium slows the rate of MTSEA modification at M37C Figure 3 
Barium slows the rate of MTSEA modification at M37C. Example of experimental paradigm used to assess Ba2+ effects 
on modification rates. (A) Successive ACh-evoked current traces recorded before and after repeated exposures to MTSEA (5 
M, 15 seconds), showing a decrement in responses to 30 M ACh. Endpoints of MTSEA modification are determined by pro-
longed application of 500 M MTSEA (right). (B) The same protocol, including Ba2+ pretreatment and co-application with 
MTSEA. Current traces are truncated in both (A) and (B) between consecutive MTSEA applications; in all cases the currents 
were allowed to return to baseline prior to the next application of MTSEA ± ACh. (C) Peak current amplitudes from (A) and 
(B) are normalized and plotted versus total MTSEA exposure time. Data from this single experiment (no error bars) are fitted 
to a single-exponential decay (solid line) to extract an apparent pseudo first-order rate constant. The pseudo first-order rate 
constants calculated in this experiment were 0.011 s-1 and 0.0019 s-1 for control (A) and +Ba2+ (B) measurements, respectively. 
Second-order rate constants are calculated from these values (Figures 4–6; Table 2).BMC Pharmacology 2009, 9:1 http://www.biomedcentral.com/1471-2210/9/1
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closed to open transition. Few studies have attempted to
address this question, but a recent report does examine
the conformational effects of positive allosteric modula-
tors (benzodiazepines) in GABAA  receptors [31]. This
study used SCAM to show that a prominent effect of ben-
zodiazepines is to increase the access of GABA to its bind-
ing site, reducing the energetic barrier to the initial step in
receptor activation, GABA association. Divalent cation
effects on 7 AChRs provide a similar paradigm in which
to examine the conformational changes evoked by
allosteric modulators.
In an earlier report we described an 7 AChR mutant with
a pair of cysteine substitutions positioned to introduce a
disulfide bond in the outer  sheet [26]. In our parental
background this mutant was fully activated by divalent
cations in the absence of ACh, but when expressed in an
7 AChR without the L247T mutation it required both ACh
and divalent cations for channel activation. If we assume
that activation of this mutant occurs as a result of Ba2+
interaction with the divalent cation allosteric site, then it
suggests that Ba2+ and ACh promote two overlapping but
distinct sets conformational changes. The experiments
presented in this report provide further evidence that con-
formational effects of divalent cations are similar to those
of elicited by ACh. Thus the simplest interpretation of our
data is that divalent cations act by enhancing transitions
in an ACh-dependent activation pathway without sub-
stantial effect on the final closed to open transition.
Le Novere and colleagues [15] proposed a model for a
divalent cation binding site that was based on earlier
experiments, homology between the 7 AChR ECD and
the Lymnea AChBP, and the known database of divalent
cation binding proteins [10,20]. The focus of this model
was a cluster of 4 negatively charged residues in the tran-
sition zone: D41, D43, E44, and E172. Mutational analysis
suggested that the glutamate residues were critical, since
charge neutralization at either of the aspartate residues
had only modest effects on divalent modulation. While
the geometry of these residues in models of the ECD is
consistent with their proposed model, our results with
Barium alters the rate of MTSEA modification at inner  sheet residues Figure 4
Barium alters the rate of MTSEA modification at inner  sheet residues. (A) Using the protocol described in Figure 
3, we determined second-order rate constants for three reporter residues in the 7 AChR inner  sheet (M37C, M40C, and 
N52C). Mean values for second-order rate constants for modification by MTSEA alone (control), MTSEA + ACh, and MTSEA + 
Ba2+ are shown. * Rate was significantly different from control (P < 0.05). (B) A plot of the ratios of second-order rate con-
stants. Ba2+ and ACh both slowed the rates of modification of M37C and M40C. At N52C, however, the rate of modification in 
the presence of Ba2+ was not significantly different from control, while ACh accelerated the modification rate. See Table 2 for 
summary including (n) for each condition.BMC Pharmacology 2009, 9:1 http://www.biomedcentral.com/1471-2210/9/1
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Ba2+-induced conformational changes are not. A mutation
of either E44 or E172 to cysteine eliminates the modulation,
but not the conformational changes associated with
Ba2+modulation. This strongly suggests that the allosteric
effects of Ba2+ are "transmitted" in a conformational path-
way that requires these glutamates for some role other
than divalent cation binding. It is unlikely that the Cys
substitution is able to act as a functional substitute for Glu
in a divalent cation site: a survey of all known Ca2+ bind-
ing sites found that Cys was never a contributor to a Ca2+
co-ordination site, while it often plays this role in Zn2+
binding sites [32]. Other possible candidates for a diva-
lent cation modulation site in the 7 ECD include acidic
residues in 6 and 8, which may combine with neigh-
boring carbonyl groups to form a site for divalent cation
binding. Alternatively, the recent work of Horn and col-
leagues [33] has demonstrated that aromatic residues may
provide the negative electrostatic environment required
for formation of a physiologically relevant divalent cation
binding site through the -cation-type interactions. This is
the same structural motif that has been shown to provide
the negative electrostatic environment in the cholinergic
agonist binding site [34].
Methods
Reagents
MTSEA (2-aminoethylmethane thiosulfonate) was
obtained from Toronto Research Chemicals (Toronto,
Canada). Gentamicin was from Invitrogen (Carlsbad,
CA). All other reagents were obtained from Sigma-Aldrich
(St. Louis, MO).
Site-directed mutagenesis
A cDNA clone of the chick 7 receptor containing two
mutations (C115A, L247T) was used as the parental pheno-
type for mutations described in this study. We mutated
the lone unpaired cysteine in the extracellular domain
(C115) to alanine to allow for a more straightforward inter-
pretation of thiol modification experiments. We observed
no functional effect of this mutation on receptor expres-
Barium alters the rate of MTSEA modification at residues required for modulation by divalent cations Figure 5
Barium alters the rate of MTSEA modification at residues required for modulation by divalent cations. Second-
order rate constants were measured for three residues in the "transition zone" of the 7 AChR (E44C, N170C, and E172C). (A) 
Mean values for second-order rate constants for modification by MTSEA alone, MTSEA + ACh, and MTSEA + Ba2+. Ba2+ caused 
a significant decrease in MTSEA modification rates of both E44C and E172C, despite the loss of divalent cation-dependent mod-
ulation. Ba2+ did not have a significant effect on the modification rate of N170C, although ACh significantly increased the rate of 
modification of this residue. *Rate was significantly different from control (P < 0.05). ‡Rate was significantly different from that 
obtained in presence of ACh (P < 0.05). The plot of rate constant ratios (B) shows that the effect of Ba2+ on the rate of modi-
fication of E44C was significantly less than the effect of ACh. See Table 2 for summary including (n) for each condition.BMC Pharmacology 2009, 9:1 http://www.biomedcentral.com/1471-2210/9/1
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sion or ACh response. We included the mutation of leu-
cine 247 in the M2 transmembrane domain (L247T; L9'T)
because of its large current amplitudes and non-desensi-
tizing kinetics compared to wild-type 7 receptors [35].
These receptors exhibit a higher "gating constant" than
wild-type 7 AChRs [36], suggesting that the closed-to-
open equilibrium of liganded C115A/L247T receptors
favors the open state. Mutation at the L247  position
enhanced the ability to measure modification rates for
cysteine replacements in which the ACh-evoked current
amplitudes are attenuated [37]. In preliminary experi-
ments, modification rates of cysteines introduced into
wild type 7 AChRs were similar to those in L247T-con-
taining receptors, suggesting that conformational changes
in the ECD of L247T-containing receptors are similar to
those in wild-type receptors (not shown). All mutations
were introduced by site-directed mutagenesis using the
QuikChange method (Agilent Technologies, La Jolla, CA)
as described previously [21], and were confirmed by DNA
sequencing.
Xenopus oocyte maintenance and expression
cRNA was prepared using the T7 RNA polymerase and
mMessage mMachine kit as described by the manufac-
turer (Applied Biosystems, Austin, TX). Oocytes were sur-
gically removed and prepared from female Xenopus laevis
in accordance with UNC Institutional Animal Care and
Use Committee guidelines. Oocytes were injected with 20
ng of cRNA and incubated at 18°C in ND96 (96 mM
NaCl, 2 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, 5 mM Na
pyruvate, 50 g/ml gentamicin, 5 mM HEPES, pH 7.5) for
2–5 days before use. For some mutants we co-injected
cRNA encoding the human RIC-3 [38], a protein shown to
enhance expression of 7 AChRs in both mammalian
cells and oocytes [39]. This co-injection (at a 1:1 ratio, 20
ng per oocyte) enhanced maximal current responses with-
out significant effect on ACh EC50 (not shown).
Data collection and analysis
Oocytes were superfused in normal extracellular solution
containing a reduced Ca2+ concentration (ESLC; 96 mM
NaCl, 2 mM KCl, 1 mM MgCl2, 0.1 mM CaCl2, and 10
mM HEPES, pH 7.5). This solution minimized Ca2+ influx
and eliminated Ca2+-activated chloride currents. Two-
electrode voltage clamp was performed with a GeneC-
lamp 500B controlled by pCLAMP8 software (Molecular
Devices, Sunnyvale, CA). Electrodes were filled with 3 M
KCl contacting Ag-AgCl wires and had resistances of 0.5 to
2.0 M. Currents were recorded at a constant holding
potential of -60 mV. Currents were low pass filtered at 50
Hz and sampled at 100 Hz. Agonist dose-response curves
were obtained as described previously [21], and data were
fit to the Hill equation using Origin software (Microcal
Software, Northampton, MA).
Expression and modification rates
Each mutant was initially screened for functional expres-
sion over a range of ACh concentrations to generate a
dose-response relationship and determine its EC50. To test
for reactivity of introduced free thiols, we compared
responses of each mutant to an ~EC50 ACh dose before
and after exposure to high concentrations of MTSEA (0.5
– 1.0 mM) applied by continuous flow for 30 to 60 sec-
onds. MTSEA was prepared daily in distilled water and
stored on ice. Stock solution was diluted to the appropri-
ate working concentration in ESLC immediately before
each application. Rates were measured by determining a
limiting dose of MTSEA (0.1–100 M), then exposing
Table 2: Summary of MTSEA modification data.
MUTANT MTSEA modification rate × 103, M-1 S-1 (n)
control + ACh + Ba2+
M37C 2.4 ± .03 (10) 0.30 ± 0.05 (4) 0.40 ± 0.02 (5)
M40C 16 ± 0.2 (13) 2.2 ± 0.4 (3) 2.8 ± 0.05 (7)
N52C 0.40 ± .08 (9) 1.4 ± 0.04 (7) 0.26 ± 0.02 (7)
E44C 23 ± 0.7 (4) 0.90 ± 0.05 (4) 9.3 ± 0.1(8)
N170Ca 3.3 ± .05 (7) 5.7 ± 0.1 (7) 3.7 ± 0.06 (9)
E172Ca 15 ± 0.4 (5) 3.5 ± 0.1 (5) 7.3 ± 0.3 (6)
M40C/E172Qa 14 ± 0.5 (5) 1.3 ± 0.1 (5) 2.0 ± 0.3 (6)
Second-order rate constants ± standard error for various conditions at each Cys mutant. (n), number of determinations.
(a) Mutants studied using co-expression with human RIC-3 (Halevi et al., 2002).BMC Pharmacology 2009, 9:1 http://www.biomedcentral.com/1471-2210/9/1
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oocytes to these low concentrations of MTSEA repeatedly
for 15–30 seconds followed by a challenge with an ~EC50
concentration of ACh. The limiting dose, yielding 20–
40% of the maximal MTSEA effect, was identified for each
mutant. To measure the effect of ACh on modification
rates we used the same protocol but included an ~EC110
ACh dose with the applied MTSEA. To measure the effect
of Ba2+ on modification rates we pre-applied 10 mM Ba2+
for 30 seconds prior to co-application of 10 mM Ba2+ plus
MTSEA. This concentration of Ba2+ is equivalent to an
approximate EC110 for the modulatory effects in both
parental and mutant AChRs. Kinetic data were analyzed as
described previously [40]; rate data were fit to a single
exponential to extract a pseudo-first order rate constant;
this was divided by the MTSEA concentration used to
determine the second order rate constant for thiol modi-
fication.
Statistical Analysis
Statistical analysis of EC50 values and second-order rate
constants was conducted using a one-way analysis of var-
iance, followed by a post hoc Tukey test. P values of < 0.05
were interpreted to indicate significant differences.
Structural models of 7
A model of the chick 7 nicotinic receptor extracellular
domain, based on the coordinates of the Lymnea  ACh
Binding Protein [10] was constructed as described previ-
Charge neutralization at E172 does not alter the rate of modification M40C by MTSEA Figure 6
Charge neutralization at E172 does not alter the rate of modification M40C by MTSEA. Mean values for second-
order modification rate constants for M40C (left, data from Fig. 3) compared to those obtained in receptors containing the 
E172Q mutation (M40C/E172Q). *Rates were significantly different from control (P < 0.05). See Table 2 for summary, including 
(n) for each condition.BMC Pharmacology 2009, 9:1 http://www.biomedcentral.com/1471-2210/9/1
Page 12 of 13
(page number not for citation purposes)
ously [23,26]. Images of the model were generated with
Pymol (DeLano Scientific, South San Francisco, CA).
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